Stephanie Krebs - Dec 20, 2024 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Chief Business Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Dec 20, 2024
Transactions value $
$0
Form type
4
Date filed
12/23/2024, 04:15 PM
Previous filing
Nov 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +120K $0.00 120K Dec 20, 2024 Common Stock 120K $0.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option shall vest on December 1, 2025, subject to the Reporting Person's continuous service with the Issuer as of such date.